Patients who require medication to treat attention deficit hyperactivity disorder continue to have a difficult time filling ...

“This is an industry which requires a high level of investment, has relatively high barriers to entry and superior quality requirements compared to other industries,” said Robert Wessman, CEO and ...

NRx Pharmaceuticals’ investigational antidepressant has failed to reach statistical significance in reducing depression ...

Alvogen is one of the fastest growing pharmaceutical companies in the world with commercial presence in over 35 countries. We improve people’s lives by making high-quality medicines more ...

opens new tab that barred rival drugmaker Alvogen from marketing a proposed generic version of Bausch's diarrhea treatment Xifaxan until 2029. A Delaware federal court had determined that Alvogen ...

The Union Budget contains details about the estimated receipts and the expenditure of the government for a particular fiscal year. The Budget is allotted for the upcoming fiscal year, which runs ...

Gutman has represented Alvogen Pine Brook, Amgen, Natco Pharma and Oxford Immunotec Global in prior patent fights. "Sige is regarded as one of the top life sciences patent litigators in the country," ...

(Reuters) - A U.S. appeals court on Thursday affirmed a decision for Bausch Health that barred rival drugmaker Alvogen from marketing a proposed generic version of Bausch's diarrhea treatment ...